COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,585 Articles (22,905 medRxiv, 8,680 bioRxiv)

Most recent first Previous |  Page 1020: Articles 10191-10200  | Next

SARS-CoV-2 impairs interferon production via NSP2-induced repression of mRNA translation
Choi, J.-H., Zhang, X., Zhang, C., Dai, D. L., Luo, J., Ladak, R., Li, Q., Wiebe, S., Liu, A. C. H., Ran, X., Yang, J., Naeli, P., Garzia, A., Zhou, L., Mahmood, N., Deng, Q., Elaish, M., Lin, R., Hobman, T., Pelletier, J., Alain, T., Vidal, S., Duchaine, T., Mazhab-Jafari, M., Mao, X., Jafarnejad, S. M., Sonenberg, N.
10.1101/2022.01.19.476693 — Posted: 2022-01-20
Pathogenicity of SARS-CoV-2 Omicron in Syrian hamsters and its neutralization with different Variants of Concern
Mohandas, S., Yadav, P. D., Sapkal, G., Shete, A. M., Deshpande, G., Nyayanit, D. A., Patil, D. Y., Kadam, M., Kumar, A., Mote, C., Jain, R.
10.1101/2022.01.19.477013 — Posted: 2022-01-20
Targeting SARS-CoV-2 infection through CAR T cells and bispecific T cell engagers
Dogan, M., Kozhaya, L., Placek, L., Karabacak, F., Yigit, M., Unutmaz, D.
10.1101/2022.01.19.476940 — Posted: 2022-01-20
Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response
Shalamova, L., Felgenhauer, U., Schaubmar, A. R., Buettner, K., Widera, M., Ciesek, S., Weber, F.
10.1101/2022.01.20.476754 — Posted: 2022-01-20
Evidence of antibodies against SARS-CoV-2 in wild mustelids from Brittany (France)
Davoust, B., Guerin, P., Orain, N., Fligny, C., Flirden, F., Fenollar, F., Mediannikov, O., Edouard, S.
10.1101/2022.01.20.477038 — Posted: 2022-01-20
Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity
Lin, J., Law, R., Korosec, C., Zhou, C., Koh, W. H., Ghaemi, M. S., Samaan, P., Ooi, H. K., Yue, F.-Y., Gingras, A.-C., Estacio, A., Buccholz, M., Cheatley, P. L., Pavenski, K., Mubareka, S., McGeer, A., Leis, J., Heffernan, J. M., Ostrowski, M.
10.1101/2022.01.18.476864 — Posted: 2022-01-20
Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants
Hu, Y.-f., Hu, J.-c., Gong, H.-R., Danchin, A., Sun, R., Chu, H., Hung, I. F.-N., Yuen, K. Y., To, K. K.-W., Zhang, B.-Z., Yau, T., Huang, J.-D.
10.1101/2022.01.19.477009 — Posted: 2022-01-20
Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants
Duty, J. A., Kraus, T. A., Zhou, H., Zhang, Y., Shaabani, N., Yildiz, S., Du, N., Singh, A., Miorin, L., Li, D., Stegman, K., Ophir, S. I., Cao, X., Atanasoff, K., Lim, R., Kowdle, S. S., Carreno, J. M., Rivero-Nava, L., Raskin, A., Moreno, E., Johnson, S., Rathnasinghe, R., Pai, C. I., Kehrer, T., Paz Cabral, E., Jangra, S., Healy, L. D., Singh, G., Warang, P., Simon, V., Sordillo, M. E., van Bakel, H., Liu, Y., Sun, W., Kerwin, L., Palese, P., Teijaro, J., Schotsaert, M., Krammer, F., Bresson, D., Garcia-Sastre, A., Fu, Y., Lee, B., Powers, C., Moran, T. M., Ji, H., Tortorella, D., Allen, R. D.
10.1101/2022.01.19.476998 — Posted: 2022-01-20
Detection and upsurge of SARS-CoV-2 Omicron variant in Islamabad Pakistan
Umair, M., Ikram, A., Rehman, Z., Haider, S. A., Badar, N., Ammar, M., Ali, Q., Aahad, A., Suleman, R., Khalid, A., Tariq, A., Jamal, Z., Salman, M.
10.1101/2022.01.13.22268997 — Posted: 2022-01-20
T cell response following anti COVID-19 BNT162b2 vaccination is maintained against the SARS-CoV-2 Omicron B.1.1.529 variant of concern
Cohen, H., Rotem, S., Elia, U., Bilinsky, G., Levy, I., Chitlaru, T., Bar-Haim, E.
10.1101/2022.01.19.476497 — Posted: 2022-01-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).